We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Cardiac Closure Device Reduces Stroke Risk

By HospiMedica International staff writers
Posted on 05 Apr 2015
Print article
The Watchman LAA closure device
The Watchman LAA closure device (Photo courtesy of )
An innovative left atrial appendage (LAA) closure device assists high-risk patients with non-valvular atrial fibrillation (AF) who are seeking an alternative to long-term warfarin therapy.

The Watchman LAA closure system consists of a delivery catheter, an access sheath that serves as a conduit for the delivery catheter, and the LAA closure device itself, which is permanently implanted at or slightly distal to the ostium of the LAA, blocking it off to prevent thrombus embolization. The Watchman LAA is made of a nitinol frame with a polyethylene terephthalate (PET) membrane cap, and is available in five diameters (21, 24, 27, 30, and 33 mm); 10 active fixation anchors provide stability and retention. The access sheath is available in either a double or single curve distal tip.

A transesophageal echocardiogram (TEE) is first performed to determine device size. The placement procedure is performed in a catheterization laboratory, using standard transseptal technique. Once the inter-atrial septum is crossed, the access sheath is advanced over a guidewire into the left atrium and onto the distal portion of the LAA over a pigtail catheter. The Watchman is then advanced under fluoroscopic guidance and deployed into the LAA. The Watchman LAA closure device is a product of Boston Scientific (Natick, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Boston Scientific is proud to offer this potentially life-changing stroke risk treatment option to high-risk patients with AF who have a reason to seek a non-drug alternative to warfarin,” said Joe Fitzgerald, executive vice president and president of rhythm management at Boston Scientific. “FDA approval of the Watchman device is another example of Boston Scientific delivering on its commitment to bring meaningful innovations to patient care.”

“The Watchman device is a breakthrough treatment providing those patients who are suitable for warfarin with an implant-based alternative to long-term warfarin therapy while still reducing the risk of stroke,” said Vivek Reddy, MD, director of the cardiac arrhythmia service at Mount Sinai Medical Center (Miami, FL, USA). “We know that up to 40% of patients who are eligible for oral anticoagulation do not take it for numerous reasons, highlighting the need for additional treatment options.”

The LAA is a small, ear-shaped sac in the muscle wall of the left atrium. In normal hearts, the heart contracts with each heartbeat, and the blood in the left atrium and LAA is squeezed out into the left ventricle. When a patient has AF, the chaotic impulses do not give the atria time to contract, and blood collects and can form clots in the LAA and atria. The LAA is thought to be the source of more than 90% of stroke-causing blood clots that come from the heart in non-valvular AF patients.

Related Links:

Boston Scientific
Mount Sinai Medical Center


Gold Supplier
Ultrasound Transducer/Probe Cleaner
Transeptic Cleaning Solution
New
Portable Manual Defibrillator
RESCUE 230
New
Portable Finger Pulse Oximeter
Onyx Vantage 9590
New
Eye Protector
Biliband
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

AI

view channel
Image: MyoVista Wavelet technology utilizes AI for early detection of heart disease (Photo courtesy of Heart Test Laboratories)

Novel ECG Technology Utilizes AI for Early Detection of Heart Disease

Cardiovascular disease is responsible for 17.9 million deaths every year, or about 32% of all deaths worldwide. Every week, millions of electrocardiographs (ECGs) are performed across the world, making... Read more

Critical Care

view channel
Image: Studies have shown the Autus Valve maintains control of blood flow as it expands (Photo courtesy of Boston Children’s Hospital)

Heart Valve That Grows Along With Child Could Reduce Invasive Surgeries

In children with congenital pulmonary valve disease, the flow of blood between the heart and lungs is impeded. In cases where the pulmonary valves have narrowed or are leaking and cannot be treated effectively... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.